2024-10-22 - Analysis Report
## Merck & Co., Inc. (MRK) Stock Analysis

**1. Relative Performance vs. S&P 500 (VOO)**

Merck & Co., Inc. (MRK) is a global pharmaceutical company engaged in the discovery, development, manufacturing, and marketing of prescription medicines and vaccines.  

MRK has underperformed the S&P 500 (VOO) with a cumulative return of 64.96% compared to VOO's 136.39%.  This represents a difference of -71.43%, which is in the 14.05th percentile of its historical performance range.

**2. Recent Price Movement**

* Closing Price: $106.17
* 5-Day Moving Average: $108.28
* 20-Day Moving Average: $110.55
* 60-Day Moving Average: $113.86

MRK is currently trading below its 5-day, 20-day, and 60-day moving averages, indicating a potential downward trend.

**3. Technical Indicators**

* RSI: 28.22 (Below 30, indicating oversold conditions)
* PPO: -0.24 (Negative value, suggesting a bearish trend)
* Delta_Previous_Relative_Divergence: -15.64 (Negative, indicating recent downward price pressure)
* Expected_Return: 0.0% (Expected long-term return, assuming a buy-and-hold strategy, is expected to be on par with the S&P 500.)

The technical indicators suggest that MRK may be undervalued and could be poised for a potential rebound. However, the negative divergence and bearish trend signal caution.

**4. Recent Earnings & Outlook**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-05 | 2.15 | $16.11B |
| 2024-05-03 | 1.88 | $15.78B |
| 2023-11-03 | 1.87 | $15.96B |
| 2023-08-07 | -2.35 | $15.04B |
| 2024-08-05 | -2.35 | $15.04B |

MRK's recent earnings have been mixed, with the latest quarter exceeding analysts' expectations. The company has shown consistent revenue growth, but profitability has been impacted by factors such as increased competition and a challenging macroeconomic environment. Analysts remain cautiously optimistic about MRK's future prospects, citing its strong pipeline of potential blockbuster drugs and its focus on innovation.

**5. News & Recent Issues**

According to FINBOLD, MRK's stock has been impacted by the overall market volatility, but some analysts remain bullish on the company's long-term potential.  The company's recent earnings report was well-received, and its pipeline of potential blockbuster drugs remains a key factor in its future growth prospects. However, concerns remain regarding the company's ability to maintain its profitability in the face of increasing competition and rising costs.

**6. Overall Analysis**

MRK is a large pharmaceutical company with a strong brand and a solid track record of innovation. The company has a diverse product portfolio and a promising pipeline of new drugs. Despite the recent underperformance compared to the S&P 500, MRK remains a fundamentally sound company with long-term growth potential. The technical indicators suggest that the stock may be undervalued, and the recent earnings report provides some confidence in its future prospects. However, the company's performance will continue to be impacted by factors such as regulatory approvals, competition, and the overall macroeconomic environment. 

**7. Recommendations**

For long-term investors with a higher risk tolerance, MRK could be considered a potential investment opportunity. However, it is essential to monitor the company's performance and the overall market conditions.  Investors should also consider diversifying their portfolios to mitigate risk. 

**Disclaimer:** This analysis is for informational purposes only and should not be considered investment advice. It is essential to conduct your own due diligence before making any investment decisions.
